NCT01098162

Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug

A Non-interventional Post-marketing Study, Evaluating Seizure Control and Tolerability of Vimpat® as Adjunctive Therapy to One Baseline Antiepileptic Drug in Epilepsy Patients With Partial-onset Seizures With or Without Secondary Generalization in Daily Clinical Practice in Germany

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 576 (actual)
• Sponsor: UCB Pharma GmbH · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®. The observed population will be only patients with one baseline antiepileptic drug. Seizure control and tolerability data will be evaluated.

Conditions

• Epilepsies, Partial

Timeline

• Start date: 2010-03-01
• Primary completion: 2013-07-01
• Completion: 2013-07-01
• First posted: 2010-04-02
• Last updated: 2014-09-03
• Results posted: 2014-07-22

Locations

113 sites across 1 country: Germany